Varithena is NOT safe in patients with active venous thrombosis
Varithena (polidocanol foam) is contraindicated or should be avoided in patients with existing venous thrombosis, as the medication itself induces thrombosis as its mechanism of action and can worsen existing clots or cause dangerous thrombus extension.
Why This Is Dangerous
The FDA label explicitly warns that Varithena can cause venous thrombosis and lists patients with "history of deep vein thrombosis or pulmonary embolism" as being at increased risk for developing thrombosis 1. The drug works by intentionally creating thrombosis in treated veins - adding more thrombotic stimulus to a patient who already has venous thrombosis creates a compounding risk.
The Evidence on Thrombotic Complications
Deep vein thrombosis (DVT) occurred in 4.7% of Varithena-treated patients in placebo-controlled trials 1. More concerning:
- Infusion site thrombosis occurred in 16.1% of patients 1
- Venous thrombosis in the limb occurred in 8.1% 1
- Recent research shows DVT rates as high as 14.7-16.7% without anticoagulation prophylaxis 2
The mechanism is straightforward: Varithena induces thrombosis in superficial veins, and this thrombus can extend into the deep venous system. In a patient who already has venous thrombosis, you're adding fuel to the fire.
Critical Safety Warnings from FDA Label
The FDA specifically states that patients with reduced mobility, history of DVT or PE are at increased risk for developing thrombosis with Varithena 1. The label instructs physicians to "monitor for signs of venous thrombosis after treatment" 1 - this monitoring becomes meaningless if the patient already has thrombosis.
D-dimer is commonly elevated post-treatment and is not useful diagnostically to assess for venous thrombus following Varithena 1. This means you lose a key diagnostic tool for monitoring thrombosis progression in a patient who already has it.
When Varithena Should Be Used
Varithena is indicated for treating incompetent saphenous veins and visible varicosities in patients with superficial venous insufficiency 1, not for patients with active thrombosis. The appropriate clinical scenario is:
- Symptomatic varicose veins with documented valvular reflux
- No active DVT or recent history of VTE
- Patient can be monitored post-procedure for thrombotic complications
The Bottom Line
If your patient has venous thrombosis, treat the thrombosis first with anticoagulation. Only consider Varithena after the thrombosis has resolved and the patient has completed appropriate anticoagulation therapy. The guidelines support endovenous thermal ablation or sclerotherapy for chronic venous disease 3, but these are for venous insufficiency, not active thrombosis.
Do not use Varithena in a patient with existing venous thrombosis - the risk of thrombus extension, propagation, and potential pulmonary embolism far outweighs any benefit from treating superficial venous insufficiency.